SFTPD and acute lymphoblastic leukemia: This specific molecular interaction highlights the precision with which SP-D exerts its anti-leukemic effects, offering a targeted approach to leukemia treatment that holds promise for the development of effective therapeutic strategies in combating cancers such as acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), and Burkitt’s lymphoma (112, 113, 119).